PURPOSE: Few large European studies have evaluated long-term outcomes for permanent prostate brachytherapy (PPB) as monotherapy for clinically localized prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The objective of the present study was to evaluate long-term survival in this patient profile.
METHODS AND MATERIALS: Retrospective study of 700 patients who underwent transperineal ultrasound-guided iodine-125 PPB (145 Gy) between January 2000 and July 2012. Median age was 64.8 years (range, 35-79). Most patients (638 of 700; 91%) had low-risk disease (D'Amico criteria). Eighty-five patients (12%) received hormonal treatment. Overall survival, cause-specific survival, and biochemical relapse-free survival were calculated and estimated using actuarial and Kaplan-Meier methods. Differences between groups were assessed using the log-rank test.
RESULTS: Median followup was 63 months (range, 6-164). At 5- and 10-year followup, respectively, overall survival was 94% (95% confidence interval [CI], 92-96) and 84% (95% CI, 78-90); cause-specific survival was 100% and 97% (95% CI, 95-99); and biochemical relapse-free survival was 95% (95% CI, 93-97) and 85% (95% CI, 79-91).
CONCLUSIONS: The long-term results presented in this report confirm previous studies and provide additional support for the use of PPB in patients with favorable-risk prostate cancer. Seed brachytherapy provides excellent long-term results in this patient profile.
Martinez E, Daidone A, Gutierrez C, Pera J, Boladeras A, Ferrer F, Pino F, Suarez JF, Polo A, Guedea F. Are you the author?
Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Radiation Oncology, Policlinico di Palermo, Universitá degli Studi di Palermo, Palermo, Italy; Department of Medical Physics, Catalan Institute of Oncology, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Urology, Hospital de Bellvitge, Barcelona, Spain; Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. .
Reference: Brachytherapy. 2015 Mar-Apr;14(2):166-72.